Lisinoratio

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lisinoratio

Property Description
Active Ingredients Lisinopril, Hydrochlorothiazide
Form Tablet (Fixed-Dose Combination)
Pharmacological Class ACE Inhibitor-Diuretic Combination
Common Use Management of High Blood Pressure (Hypertension)
Origin Synthetic

Lisinoratio: A Fixed-Dose Combination Antihypertensive

Lisinoratio is a well-recognized synthetic, prescription-only combination medicine categorized as an antihypertensive agent used to manage high blood pressure in adults. It is supplied as an oral tablet and is distinguished by being a fixed-dose combination (FDC) that contains two chemically different active substances. This dual-component approach is clinically recognized for providing superior blood pressure control compared to using a single agent and is an established strategy in cardiovascular medicine. The FDC format, also present in other popular formulations like Prinzide, simplifies the treatment regimen for patients requiring the combined benefits of two drug classes.

Composition, Class, and Purpose

Lisinoratio contains the active ingredients Lisinopril and Hydrochlorothiazide (HCTZ). Lisinopril is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor, while Hydrochlorothiazide is a thiazide diuretic. The preparation therefore belongs to the ACE inhibitor-diuretic combinations pharmacological group. The core purpose of Lisinoratio therapy is to provide effective, simultaneous dual-action support for the long-term control of hypertension. This combined effect works to reduce chronic strain on the heart and arteries by simultaneously promoting vasodilation (vessel widening) and encouraging volume reduction (fluid removal).

What side effects are possible with Lisinoratio?

Lisinoratio's official safety profile, documented by regulatory authorities, describes adverse reactions classified by frequency and affected body system.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped based on their clinical occurrence rates:

  • Common (may affect up to 1 in 10 people): Cough (a class effect of the ACE inhibitor component), headache, dizziness, fatigue, and gastrointestinal effects like diarrhea or nausea.
  • Uncommon (may affect up to 1 in 100 people): Orthostatic effects (dizziness upon standing), paresthesia, and skin rash.
  • Rare (may affect up to 1 in 1,000 people): Angioedema, acute renal failure, jaundice, and hyperkalemia.

Clinically Significant and Serious Adverse Reactions

Regulatory labeling highlights reactions that are rare but clinically critical. These include Angioedema (swelling of the face, tongue, or throat), which is an absolute restriction for future use of ACE inhibitors, and severe organ issues such as Acute Renal Failure and signs of Hepatic Failure (jaundice). Very rare, severe effects on blood cell production, such as Bone Marrow Depression, are also documented.

Safety Considerations for Specific Populations

Official documents define constraints for certain groups. Use of Lisinoratio is contraindicated in severe renal impairment (creatinine clearance less than 30 mL/min) and severe hepatic impairment. Furthermore, its use is associated with fetal injury and death during the second and third trimesters of pregnancy. Symptomatic hypotension is noted as being most likely to occur following the initial dose or upon dose increase, especially in patients with pre-existing fluid depletion.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the overdose profile for Lisinoratio (Lisinopril/Hydrochlorothiazide) based on severe physiological disturbances. The primary documented clinical manifestation of overdose is profound hypotension (severe low blood pressure), which carries a risk of leading to shock and cardiocirculatory collapse. Other potential severe outcomes include Acute Renal Failure.

Overdose manifestations also commonly include signs of volume and electrolyte depletion, such as dehydration, dizziness, confusion, weakness, and imbalance of serum electrolytes (e.g., hyperkalaemia, hypokalaemia). Cardiac effects like bradycardia (slow heart rate) or tachycardia (fast heart rate) are also documented.

Required Emergency Actions

Immediate medical attention must be sought upon any suspicion of overdose, even if initial symptoms are absent. Contact with a poison control center or emergency services is mandated by regulatory bodies. Urgent medical evaluation is required if the individual experiences severe hypotension, has a seizure, collapses, or has trouble breathing.

Management is strictly symptomatic and supportive, aiming to correct fluid and electrolyte imbalances. No specific antidote is known for the Lisinopril component. Procedures like gastric lavage or activated charcoal administration may be considered soon after ingestion to limit systemic absorption, followed by continuous monitoring of vital signs and renal function.

Therapeutic Uses of Lisinoratio

Lisinoratio is a type of medication commonly used to address several significant cardiovascular conditions. It is applied across domains where additional symptomatic support is needed and helps manage symptoms related to heightened physiological activity and systemic imbalance.

Its therapeutic domain is relevant for easing conditions presenting with systemic or localized discomfort. The main uses include the management of hypertension (high blood pressure), adjunct therapy for heart failure, and supportive symptom management following an acute myocardial infarction (heart attack). These applications contribute to easing the overall symptom load and may assist with maintaining functional stability during symptomatic periods. The medication supports patients during episodes of heightened discomfort associated with chronic cardiovascular burden, providing supportive relief when symptoms interfere with routine activities. This provides support that helps ease the overall symptom burden and is often used during phases when symptoms become more noticeable.


Quick Facts: Relevant for easing symptoms related to heightened physiological activity and systemic imbalance.

Regulatory References

  1. LISINOPRIL tablet - DailyMed - NIH

Eligibility and Restrictions for Use

Lisinoratio (Lisinopril/Hydrochlorothiazide) is officially approved for use in adults for the management of high blood pressure. Regulatory labeling strictly defines specific populations and conditions for whom the medicine is contraindicated or not recommended.

Contraindications and Prohibitions

Absolute prohibitions for using Lisinoratio include:

  • A history of angioedema (severe swelling) related to previous ACE inhibitor therapy, or having hereditary/idiopathic angioedema.
  • Known hypersensitivity to any component, or to any other sulfonamide-derived drugs (due to the Hydrochlorothiazide component).
  • Pregnancy during the second and third trimesters. Discontinuation is required immediately upon detection of pregnancy.
  • The presence of anuria (absence of urine formation).
  • Concurrent use with a Neprilysin inhibitor (e.g., Sacubitril), or within 36 hours of using one.
  • Concurrent use with Aliskiren in patients with Diabetes Mellitus.

Specific Population Restrictions

  • Children and Adolescents (under 18): Use is not recommended as safety and efficacy have not been established.
  • Severe Organ Impairment: The combination is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min) or severe hepatic impairment.
  • Renal Insufficiency ( CrCl leq 80 mL/min): Use of the fixed-dose combination should be restricted until the individual components have been titrated to determine the appropriate dose. Use is also not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Lisinoratio


Interaction Scope

  • Medicinal product categories with documented interactions: Renin-Angiotensin System (RAS) Inhibitors, Potassium-Sparing Diuretics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), mTOR Inhibitors, Lithium preparations, Bile-acid sequestering agents, Other Antihypertensive Agents, Alcohol, and Potassium Supplements.
  • Specific interacting medicines (if explicitly listed): Sacubitril/Valsartan, Aliskiren, Lithium, and mTOR Inhibitors (e.g., Everolimus).
  • Mechanistic basis of interactions (only if stated in label): Interactions are documented to stem from a reduced renal clearance of Lithium and the inhibition of the Angiotensin-Converting Enzyme (ACE), which is linked to an increased risk of angioedema. Reduced absorption of thiazides by sequestering agents is also noted.
  • Timing-based interaction rules (if applicable): Co-administration with Sacubitril-containing medicines is contraindicated and requires a mandatory 36-hour separation window.
  • Population-specific interaction notes (if applicable): The combination with Aliskiren is contraindicated in patients with Diabetes Mellitus or documented Renal Impairment.

Interaction Classifications (High-Level)

  • Interaction severity classification (as defined in official documents): Contraindicated, Clinically significant.
  • Regulatory basis (EMA / FDA / etc.): Based on official government prescribing information.
  • Interaction-context constraints (as defined in official documents): Constraints include managing the risk of Hyperkalemia with potassium-altering agents and mitigating the risk of renal function deterioration with NSAIDs.

Resulting Interaction Structure

  • Official interaction statements: Co-administration with Sacubitril/Valsartan is contraindicated. The combination with Aliskiren is contraindicated under specific renal/diabetic conditions. Potassium-Sparing Diuretics and Potassium Supplements carry a documented increased risk of Hyperkalemia. NSAIDs may cause a reduction in the antihypertensive effect. Lithium exposure is increased, risking toxicity. mTOR Inhibitors increase the documented risk of Angioedema. Bile-acid sequestering agents may reduce the absorption of the Hydrochlorothiazide component.
  • Connection to the overall interaction profile (2–4 sentences): Regulatory documentation defines this product’s interaction structure around mandatory restrictions concerning the Renin-Angiotensin System components and pharmacodynamic reinforcement of electrolyte and hypotensive effects. The profile also highlights pharmacokinetic alterations affecting co-administered substances like Lithium, as stated in the official labels.

Mechanism of Action

Lisinoratio functions as a competitive inhibitor of the angiotensin-converting enzyme (ACE), a zinc-containing metalloprotease that is a component of the Renin–Angiotensin–Aldosterone System (RAAS).

ACE is responsible for the enzymatic conversion of the decapeptide angiotensin I to the octapeptide angiotensin II. By blocking the active site of ACE, Lisinoratio prevents this conversion. The resultant reduction in circulating and tissue-local angiotensin II concentration leads to two primary downstream effects.

First, decreased angiotensin II diminishes its agonizing action on the angiotensin II type 1 ( AT1) receptors located on vascular smooth muscle cells. This antagonism of the AT1 receptor-mediated vasoconstriction results in systemic vasodilation. Second, reduced angiotensin II levels suppress the stimulation of aldosterone release from the adrenal cortex. This cascade leads to decreased aldosterone-mediated sodium and water reabsorption and a concurrent reduction in potassium excretion in the renal collecting ducts.

Collectively, the systemic vasodilation and the modulation of renal salt and water handling result in a net decrease in peripheral vascular resistance and an increase in natriuresis.

Dosage and Administration Information

Instruction Map: How to use Lisinoratio — Administration Guidelines

This map summarizes the usage instructions for the Lisinoratio (Lisinopril/Hydrochlorothiazide) fixed-dose combination tablet.

Instruction Detail
Route of Administration The fixed-dose combination is intended for oral administration.
Dosing Schedule Lisinoratio is typically taken once daily. Initial doses range from 10 mg/12.5 mg to 20 mg/12.5 mg once daily. Dose adjustments are typically made every two to four weeks, with a maximum limit of 80 mg lisinopril / 50 mg HCTZ per day.
Timing in relation to meals (if applicable) The tablet may be taken with or without food.
Preparation Requirements (if applicable) No preparation, such as dilution or reconstitution, is required for the tablet.
Age-Group Administration Rules The combination product's safety and effectiveness have not been established in children. Use in older adults requires close monitoring due to potential age-related organ function changes.
Missed-Dose Rules If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped. Double doses should not be taken.
Special Procedural Conditions The fixed-dose combination is not indicated for use as initial therapy for hypertension. Prior diuretic therapy should be discontinued for 2 to 3 days before initiation, if feasible.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Once daily (q.d.)
Use-context constraints Not for initial therapy; use is contraindicated in patients with severe renal impairment (creatinine clearance leq 30 mL/min).

Resulting Procedural Structure

Step sequence:

  • Determine the appropriate starting dose, which is typically one of the lower available strengths.
  • Administer the tablet orally once daily, irrespective of meal consumption.
  • Assess the need for adjustment every 2 to 4 weeks to maintain control.
  • Do not administer the combination to patients with severe kidney function limitation.

Connection to the overall use protocol (2–4 sentences): The administration protocol for Lisinoratio is standardized for once-daily oral intake, establishing a consistent routine for long-term management. The instruction that the combination is not for initial therapy guides its use as a step-up treatment after monotherapy. This protocol provides precise limits for dosing and frequency, while also defining a critical restriction based on renal function that must be followed.

Recent Clinical Evidence

Research evidence / Overview of studies for Lisinoratio

Research into Lisinoratio, a fixed-dose combination medicine containing Lisinopril (an ACE inhibitor) and Hydrochlorothiazide (a diuretic), includes studies such as randomized controlled trials and large-scale systematic reviews. This evidence base is used in research exploring how outcomes monitoring physiological strain or stress are measured in specific health contexts.


Evidence for use in Managing High Blood Pressure (Hypertension)

Research for managing high blood pressure mainly relies on Randomized Controlled Trials (RCTs). The studies included comparisons of the fixed combination to monotherapy (Lisinopril or Hydrochlorothiazide alone) and to inactive placebo treatments. Research examined outcomes related to systemic or functional imbalance by tracking changes in both systolic and diastolic blood pressure measurements over defined time intervals. Trials reported on the patterns of blood pressure measurements observed when the two components were used together, which were compared to observations when only one active component was used.

Research, including systematic analysis and large outcome studies, tracked the occurrence of major cardiovascular events—including heart attack and stroke—in patient groups using this type of dual-action therapy. However, evidence suggests that the Hydrochlorothiazide (HCTZ) component, when studied in large trials, is associated with limited information regarding long-term outcomes in preventing major cardiovascular events.


Evidence Context in Heart Failure and Post-Myocardial Infarction

Research exploring the use in heart failure and after a heart attack primarily focused on the evidence base for the Lisinopril component alone. These large-scale trials reported on the event rates (such as death or hospitalization) observed in patient cohorts following an acute cardiac event. The specific evidence base for the fixed-dose combination (Lisinoratio) in these conditions is limited and relies heavily on the established data for the Lisinopril component. This means comparative evidence for the fixed combination versus its components administered separately in these specialized cardiac contexts is lacking.


What Remains Uncertain and Areas for Future Research

Regulatory and peer-reviewed scientific summaries highlight several areas where research is ongoing. A key gap is the need for more comparative evidence regarding the long-term cardiovascular event outcomes associated with the Hydrochlorothiazide (HCTZ) component. Further research is also needed to better characterize the variability in blood pressure control near the end of the dosing interval. Data remains insufficient to fully characterize long-term outcomes for certain coexisting conditions or for specific, smaller racial and ethnic subgroups.

Key Studies & References DailyMed: LISINOPRIL tablet Drug Label Information

Frequently Asked Questions (FAQ)

Common questions about Lisinoratio (FAQ)

Q: How long does it usually take for Lisinoratio to start working?

A: Regulatory documents indicate that the blood pressure-lowering effect of the lisinopril component can typically begin within one hour after administration, with the peak blood pressure reduction often observed around six hours. However, achieving optimal blood pressure control may take longer, often requiring two to four weeks of treatment before the full effect is sustained.

Q: Can Lisinoratio affect kidney function, and if so, how is that monitored?

A: Official information states that Lisinoratio can affect kidney function, which is why its use is contraindicated in cases of severe kidney impairment. For patients with pre-existing conditions, regulatory guidance advises close follow-up. The need for monitoring, which often involves blood tests, is determined by a healthcare professional.

Q: What have studies shown about the long-term safety of Lisinoratio?

A: Clinical trials evaluate the safety profile over defined treatment periods, documenting side effects based on how often they occur (common, uncommon, rare). The official safety profile for long-term use is defined by these findings, which also note specific serious, but rare, risks such as severe organ issues (hepatic or renal failure).

Q: What foods or supplements should be avoided while on Lisinoratio?

A: The official product information advises caution regarding products that increase the body’s potassium levels. Therefore, official documents advise avoiding the use of potassium supplements and salt substitutes that contain potassium, due to the increased risk of hyperkalemia (high potassium).

Q: Is Lisinoratio safe for individuals with diabetes?

A: Regulatory documents state that patients with diabetes require special caution and careful blood sugar monitoring while using this medication, due to the potential for changes in blood sugar levels. Additionally, official information notes the drug is contraindicated for use alongside Aliskiren in patients who have diabetes or renal impairment.

Q: What should I do if my blood pressure drops too low while taking Lisinoratio?

A: Symptomatic hypotension (very low blood pressure) is noted as a risk, particularly following the initial dose. Official guidance advises that individuals experiencing symptoms like dizziness, lightheadedness, or feeling faint should contact their healthcare provider promptly. Caution is generally advised when changing positions, such as standing up quickly.

Q: Do users report needing adjustments to their Lisinoratio dose over time?

A: Official regulatory guidance notes that the blood pressure-lowering effect may diminish toward the end of the 24-hour dosing interval for the single-ingredient components. This suggests that monitoring blood pressure just prior to dosing is needed to determine if maintenance dose adjustments are required to sustain consistent control throughout the entire day.

Q: Does Lisinoratio typically cause weight gain or loss?

A: General weight gain or loss is not listed as a common or frequent side effect in the official safety profile. However, rare but serious side effects, such as swelling (angioedema) or signs of fluid retention, may appear as rapid, unexplained weight changes and should be discussed with a healthcare professional promptly.

Q: Is Lisinoratio considered a type of blood thinner?

A: No. Lisinoratio is an Angiotensin-Converting Enzyme (ACE) inhibitor combined with a diuretic. It functions by relaxing blood vessels and reducing fluid volume to lower blood pressure. This mechanism is distinct from a blood thinner (anticoagulant or antiplatelet) which works to prevent blood clotting.

Q: What happens if I stop taking Lisinoratio suddenly?

A: Official guidance cautions against stopping blood pressure medications suddenly. Abrupt cessation of an ACE inhibitor, like Lisinoratio, may lead to a rapid rebound increase in blood pressure. Regulatory documents indicate this may increase the risk of certain cardiovascular events.

Q: Does the time of day I take Lisinoratio make a difference?

A: Official product guidance states that the tablet should be taken once daily, with or without food. Because the medicine has a diuretic component, morning administration is often referenced to minimize the potential for disruption of nighttime sleep due to increased urination.

Q: What are the typical non-heart-related uses for Lisinoratio?

A: According to official regulatory documents, Lisinoratio is only indicated (officially approved) for the treatment of hypertension (high blood pressure). The combination product is not indicated for uses beyond this purpose in the official labeling.

Q: Can Lisinoratio affect sleep patterns?

A: Official adverse reaction reports include side effects that may indirectly affect sleep, such as dizziness, headache, and drowsiness (somnolence). Also, because the medication has a diuretic component, taking it late in the day may increase the need to urinate, potentially disrupting sleep.

Q: What are the general guidelines for using Lisinoratio before surgery?

A: Official guidance highlights the risk that patients undergoing major surgery or anesthesia may experience severe hypotension (critically low blood pressure). Some regulatory guidelines state that temporarily withholding the drug for approximately 24 hours before elective surgery may be considered to mitigate this risk.

Q: How quickly do the benefits of Lisinoratio wear off after stopping the medicine?

A: The blood pressure-lowering effects of the medicine are sustained for at least 24 hours with once-daily dosing. When the medicine is discontinued, the effect generally begins to fade, with blood pressure levels typically returning to pre-treatment levels within a matter of days following discontinuation.

Q: Is Lisinoratio safe to use while breastfeeding?

A: Official regulatory information states that the active components of the drug are present in human milk. Guidance states that a decision should be made regarding whether to discontinue nursing or discontinue the medication, taking into account the importance of the drug to the mother.

Q: Does Lisinoratio affect male sexual health?

A: While not frequently reported, official adverse reaction sections sometimes include effects on male sexual health, such as impotence or a decrease in libido. These urogenital effects are typically listed as rare or having an unknown frequency in regulatory documentation.

Q: Can Lisinoratio cause changes in taste perception?

A: Official regulatory documentation indicates that the lisinopril component has been reported to potentially cause taste disturbance (dysgeusia). This effect is generally not listed as a common occurrence.

Q: What are the official recommendations for storing Lisinoratio?

A: Official storage instructions typically advise keeping the tablets at controlled room temperature, usually between 68 F and 77 F (20 C and 25 C). The container should be kept tightly closed and protected from moisture to ensure the stability of the medicine.

Q: Can Lisinoratio cause photosensitivity (increased sensitivity to the sun)?

A: Yes. Official warnings note that the hydrochlorothiazide component in the tablet may potentially cause photosensitivity (increased sensitivity to sunlight). Regulatory guidance advises patients to take precautions like avoiding excessive sun exposure, including tanning beds, and using protective clothing and sunscreen.

How should Lisinoratio be stored and disposed of?

The storage and disposal of Lisinoratio tablets must strictly follow the requirements defined in official regulatory labeling.

Requirement Storage Condition
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep away from excess heat and moisture and direct light; do not freeze.
Container Store in the original, tightly closed, light-resistant container.
Child Safety Must be kept out of the sight and reach of children.

Unused or expired Lisinoratio must be disposed of in accordance with local requirements and should not be thrown into the household trash or flushed down the toilet, unless specifically instructed by a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lisinoratio found in:

A-Z Index: